Related Tags >> Amgen Aranesp Procrit Anemia

Epogen News

Most Popular Epogen Story

Amgen's new meds beat estimates as anemia drugs slip

January 27, 2012 — 11:56am ET | By Tracy Staton

Amgen's ($AMGN) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen. New bone drugs Xgeva and Prolia beat analyst estimates for their first full Read more...

Latest Headlines

Amgen's new meds beat estimates as anemia drugs slip
January 27, 2012
Amgen strikes Epogen deals with DaVita, Fresenius
November 21, 2011
Class-action securities suit goes forward against Amgen
November 9, 2011
Medicare affirms rule expected to erode Epogen sales
November 2, 2011
Amgen sets aside $780M for marketing settlement
October 25, 2011
CMS pitches new rules for Amgen anemia meds
July 5, 2011
CMS keeps status quo on Amgen's anemia meds
June 17, 2011
Anemia meds didn't work as hoped in heart attack study
May 12, 2011
CMS panel doubts data on ESAs for transplants
January 20, 2011
FDA panel to weigh Amgen, J&J drug limits
October 15, 2010
Amgen, J&J recall anemia treatments
September 24, 2010
Medicare rules threaten Epogen with 38% drop
July 27, 2010
Medicare mulls new restrictions on anemia meds
June 17, 2010
Panel sees risks in Amgen, J&J anemia drugs
March 25, 2010
Will CMS restrict anemia-drug reimbursements?
March 22, 2010
Anemia drugs get new FDA safety plan
February 17, 2010
Study: Anemia meds double clot risk
November 11, 2009
Medicare panel to review anemia meds
August 21, 2009
Analysts: Amgen most at risk from biogenerics
July 17, 2009
Court dismisses Amgen off-label case
December 23, 2008

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Hottest Products

Featured Jobs

Events

Epogen News

Most Popular Epogen Story

Amgen's new meds beat estimates as anemia drugs slip

Latest Headlines

Paid Research Reports

THE FIERCEMARKETS NETWORK